|
Our lead SUN-B 09, is a prodrug of a currently marketed drug used as a skeletal muscle relaxant. SUN-B09 is currently in preclinical studies.
We expect SUN-B09 to find use in the treatment of spasm related disorders, such as those associated with cerebrovascular injuries, cerebral palsy, multiple sclerosis, spinal lesions and head injury.
The molecule’s physicochemical and structural features have been modified for better absorption through the gastric tract. SUN-B09 is eventually metabolized with enzymes that are widely present in the body. The molecule can easily be formulated into an injectable and once-a-day dosage form.
Preclinical and acute toxicity studies on SUN-B09 are ongoing. In animal models, the lead has shown much better absorption and efficacy, compared to the competing drug.
| 
Active Projects in Drug Discovery in focused therapy areas with known biology.
